## Miguel Angel Descalzo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3478840/publications.pdf

Version: 2024-02-01

89 papers 2,891 citations

201385 27 h-index 52 g-index

93 all docs 93 docs citations

93 times ranked 3684 citing authors

#	Article	IF	CITATIONS
1	The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry. Journal of Dermatological Treatment, 2022, 33, 2110-2117.	1.1	4
2	Complications Associated with Mohs Micrographic Surgery: Data from the Nationwide Prospective Cohort REGESMOHS. Dermatology, 2022, 238, 320-328.	0.9	4
3	[Translated article] Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer – Basal Cell Carcinoma or Squamous Cell Carcinoma – Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study. Actas Dermo-sifiliográficas, 2022, 113, T451-T458.	0.2	1
4	Association of skin diseases, biological treatment and COVIDâ€19 during the first wave of the pandemic. British Journal of Dermatology, 2021, 184, 194-194.	1.4	0
5	Mohs micrographic surgery in dermatofibrosarcoma protuberans: Rate and risk factors for recurrence in a prospective cohort study from the Spanish Registry of Mohs Surgery (REGESMOHS) and review of the literature. Experimental Dermatology, 2021, 30, 717-722.	1.4	4
6	Should methyldibromo glutaronitrile continue to be used in the European baseline Series? A <scp>REIDAC </scp> national crossâ€sectional study. Contact Dermatitis, 2021, 85, 572-577.	0.8	7
7	Patients with primary cutaneous lymphoma are at risk for severe COVIDâ€19. Data from the Spanish Primary Cutaneous Lymphoma Registry. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e624-e626.	1.3	8
8	Risk Factors and Rate of Recurrence after Mohs Surgery in Basal Cell and Squamous Cell Carcinomas: A Nationwide Prospective Cohort (REGESMOHS, Spanish Registry of Mohs Surgery). Acta Dermato-Venereologica, 2021, 101, adv00602.	0.6	8
9	Incidence of Infectious Adverse Events in Patients With Rheumatoid Arthritis and Spondyloarthritis on Biologic Drugs—Data From the Brazilian Registry for Biologics Monitoring. Journal of Clinical Rheumatology, 2020, 26, 73-78.	0.5	11
10	The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study. Journal of the American Academy of Dermatology, 2020, 82, 738-741.	0.6	4
11	Trend of relevant contact allergens of the feet in Spain over a period of 10 years. Contact Dermatitis, 2020, 82, 211-217.	0.8	3
12	State of the art of Mohs surgery for rare cutaneous tumors in the Spanish Registry of Mohs Surgery (REGESMOHS). International Journal of Dermatology, 2020, 59, 321-325.	0.5	5
13	Systemic rituximab for the treatment of the indolent forms of primary cutaneous B-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry. Journal of the American Academy of Dermatology, 2020, 83, 1535-1538.	0.6	4
14	Missing outcome data management in acute stroke trials testing iv thrombolytics. Is there risk of bias?. European Stroke Journal, 2020, 5, 148-154.	2.7	4
15	Efficiency in patch testing: the number needed to test to get one relevant result as a new approach in the evaluation of baseline series. British Journal of Dermatology, 2020, 183, 391-393.	1.4	10
16	Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. Journal of the American Academy of Dermatology, 2020, 83, 139-150.	0.6	37
17	Clinical research in Dermatology: resources and activities associated with a higher scientific productivity. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 386-391.	0.8	3
18	Matching burden of skin diseases, demand for dermatological consultations and clinical research activity: results from three national studies. British Journal of Dermatology, 2019, 182, 225-227.	1.4	0

#	Article	IF	Citations
19	No association between smoking and sentinel lymph node metastasis and survival in cutaneous melanoma. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2283-2290.	1.3	6
20	Women with moderateâ€toâ€severe psoriasis in Spain ( <scp>BIOBADADERM </scp> registry) show more than a 50% reduction in ageâ€adjusted fertility rate when compared with the general population. British Journal of Dermatology, 2019, 181, 1085-1087.	1.4	14
21	Survival analysis and sentinel lymph node status in thin cutaneous melanoma: A multicenter observational study. Cancer Medicine, 2019, 8, 4235-4244.	1.3	42
22	Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR. Clinical Rheumatology, 2019, 38, 2129-2139.	1.0	8
23	La prevalencia de psoriasis y su estimación mediante registros electrónicos. Actas Dermo-sifiliográficas, 2019, 110, 339-340.	0.2	O
24	Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study. Journal of Dermatological Treatment, 2019, 30, 461-465.	1.1	27
25	Análisis de la proporción de derivaciones potencialmente evitables desde Atención Primaria a DermatologÃa por lesiones quÃsticas o tumorales benignas en España. Datos del estudio DIADERM. Actas Dermo-sifiliográficas, 2019, 110, 659-665.	0.2	9
26	¿Existe variación en los diagnósticos dermatológicos entre la temporada de frÃo vs. calor? Un subanálisis del estudio DIADERM (España 2016). Actas Dermo-sifiliográficas, 2019, 110, 734-743.	0.2	7
27	Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study. Journal of the American Academy of Dermatology, 2018, 78, 798-800.	0.6	6
28	La investigación clÃnica en la Academia Española de DermatologÃa y VenereologÃa vista desde su corazón. Actas Dermo-sifiliográficas, 2018, 109, 99.	0.2	0
29	Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland. British Journal of Dermatology, 2018, 179, 863-871.	1.4	19
30	Systematic review of the prevalence of nodal metastases and the prognostic utility of sentinel lymph node biopsy in cutaneous squamous cell carcinoma. Journal of Dermatology, 2018, 45, 781-790.	0.6	32
31	Clinical Research at the Heart of the Spanish Academy of Dermatology and Venereology. Actas Dermo-sifiliográficas, 2018, 109, 99.	0.2	O
32	Investigación clÃnica en dermatologÃa y venereologÃa de centros e instituciones españolas, 2005-2014. Resultados del estudio MaINDH. Actas Dermo-sifiliográficas, 2018, 109, 52-57.	0.2	11
33	Sentinel lymph node biopsy versus observation in thick melanoma: A multicenter propensity score matching study. International Journal of Cancer, 2018, 142, 641-648.	2.3	20
34	Mohs micrographic surgery in the elderly: comparison of tumours, surgery and firstâ€year followâ€up in patients younger and older than 80 years old in <scp>REGESMOHS</scp> . Journal of the European Academy of Dermatology and Venereology, 2018, 32, 108-112.	1.3	20
35	Author's reply to: Prognosis of sentinel lymph node biopsy in patients with thick melanoma by a propensity score matching prospective study. International Journal of Cancer, 2018, 142, 1504-1504.	2.3	O
36	Evaluación de indicadores de estructura en la atención al paciente con cáncer de piel en los servicios de dermatologÃa. Actas Dermo-sifiliográficas, 2018, 109, 807-812.	0.2	6

#	Article	IF	Citations
37	Differences of Mohs micrographic surgery in basal cell carcinoma versus squamous cell carcinoma. International Journal of Dermatology, 2018, 57, 1375-1381.	0.5	10
38	Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1021-1028.	1.3	8
39	Psoriasis, Metabolic Syndrome, and Systematic Reviews. Actas Dermo-sifiliográficas, 2017, 108, 323.	0.2	O
40	Report from the first European Dermato-Epidemiology Network forum. British Journal of Dermatology, 2017, 177, e168-e171.	1.4	0
41	Study of Cognitive Function in Children Treated with Propranolol for Infantile Hemangioma. Pediatric Dermatology, 2017, 34, 554-558.	0.5	16
42	Epidemiological role of dogs since the human leishmaniosis outbreak in Madrid. Parasites and Vectors, 2017, 10, 209.	1.0	28
43	Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry. Journal of Investigative Dermatology, 2017, 137, 313-321.	0.3	94
44	Modelling the current distribution and predicted spread of the flea species Ctenocephalides felis infesting outdoor dogs in Spain. Parasites and Vectors, 2017, 10, 428.	1.0	16
45	Estimating the burden of influenzaâ€essociated hospitalizations and deaths in Central America. Influenza and Other Respiratory Viruses, 2016, 10, 340-345.	1.5	27
46	Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0. Rheumatology International, 2014, 34, 953-961.	1.5	50
47	Performance of the Assessment of Spondyloarthritis International Society criteria for the classification of spondyloarthritis in early spondyloarthritis clinics participating in the ESPERANZA programme. Rheumatology, 2014, 53, 353-360.	0.9	35
48	Validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme. Annals of the Rheumatic Diseases, 2014, 73, 1350-1355.	0.5	46
49	Reducing the Need for Central Dual-Energy X-Ray Absorptiometry in Postmenopausal Women: Efficacy of a Clinical Algorithm Including Peripheral Densitometry. Calcified Tissue International, 2013, 93, 62-68.	1.5	3
50	Tackling missing radiographic progression data: multiple imputation technique compared with inverse probability weights and complete case analysis. Rheumatology, 2013, 52, 331-336.	0.9	6
51	Cutaneous Adverse Events During Treatment of Chronic Inflammatory Rheumatic Conditions With Tumor Necrosis Factor Antagonists: Study Using the Spanish Registry of Adverse Events of Biological Therapies in Rheumatic Diseases. Arthritis Care and Research, 2013, 65, 2024-2031.	1.5	52
52	Patient-acceptable Symptom State as an Outcome Measure in the Daily Care of Patients with Ankylosing Spondylitis. Journal of Rheumatology, 2012, 39, 1424-1432.	1.0	17
53	Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Annals of the Rheumatic Diseases, 2012, 71, 382-385.	0.5	61
54	Variabilidad en el consumo de recursos en pacientes con espondiloartritis en España. Datos descriptivos preliminares del estudio emAR II. ReumatologÃa ClÃnica, 2012, 8, 114-9.	0.2	13

#	Article	IF	CITATIONS
55	Characteristics of Patients With Spondyloarthritis Followed in Rheumatology Units in Spain. emAR II Study. ReumatologÃa ClÃnica (English Edition), 2012, 8, 107-113.	0.2	14
56	Variability in Resource Consumption in Patients With Spondyloarthritis in Spain. Preliminary Descriptive Data From the emAR II Study. ReumatologÃa ClÃnica (English Edition), 2012, 8, 114-119.	0.2	8
57	Implications of a New Radiological Approach for the Assessment of Paget Disease. Calcified Tissue International, 2012, 91, 409-415.	1.5	15
58	Effectiveness of a clinical practice intervention in early rheumatoid arthritis. Arthritis Care and Research, 2012, 64, 321-330.	1.5	17
59	Characteristics of early arthritis units that may be associated with better referral efficiency: survey of SERAP units. ReumatologÃa ClÃnica (English Edition), 2011, 7, 236-240.	0.2	3
60	Mapping the Current Distribution and Predicted Spread of the Leishmaniosis Sand Fly Vector in the Madrid Region (Spain) Based on Environmental Variables and Expected Climate Change. Vector-Borne and Zoonotic Diseases, 2011, 11, 799-806.	0.6	56
61	Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. Medicina ClÃnica, 2011, 137, 533-540.	0.3	72
62	Cancer in Patients with Rheumatic Diseases Exposed to TNF Antagonists. Seminars in Arthritis and Rheumatism, 2011, 41, 71-80.	1.6	94
63	Questionnaire-based survey on the clinical management of canine leishmaniosis in the Madrid region (central Spain). Preventive Veterinary Medicine, 2011, 102, 59-65.	0.7	16
64	Infectivity to Phlebotomus perniciosus of dogs naturally parasitized with Leishmania infantum after different treatments. Parasites and Vectors, 2011, 4, 52.	1.0	55
65	Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. Rheumatology, 2011, 50, 1999-2004.	0.9	44
66	Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. Rheumatology, 2011, 50, 85-92.	0.9	36
67	The economic and nutrition transition in Equatorial Guinea coincided with a double burden of overand under nutrition. Economics and Human Biology, 2010, 8, 80-87.	0.7	24
68	Accuracy of an Immunochromatographic Diagnostic Test (ICT Malaria Combo Cassette Test) Compared to Microscopy among under Five-Year-Old Children when Diagnosing Malaria in Equatorial Guinea. Malaria Research and Treatment, 2010, 2010, 1-6.	2.0	6
69	Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Annals of the Rheumatic Diseases, 2010, 69, 1751-1755.	0.5	96
70	Biobadaser 2.0: analysis and trends in 2009. ReumatologÃa ClÃnica (English Edition), 2010, 6, 240-243.	0.2	3
71	Seasonal trends and spatial relations between environmental/meteorological factors and leishmaniosis sand fly vector abundances in Central Spain. Acta Tropica, 2010, 115, 95-102.	0.9	88
72	Efficacy of Artesunate + Sulphadoxine-Pyrimethamine (AS + SP) and Amodiaquine + Sulphadoxine-Pyrimethamine (AQ + SP) for UncomplicatedfalciparumMalaria in Equatorial Guinea (Central Africa). Journal of Tropical Medicine, 2009, 2009, 1-7.	0.6	8

#	Article	IF	Citations
73	Nutritional and socio-economic factors associated with Plasmodium falciparum infection in children from Equatorial Guinea: results from a nationally representative survey. Malaria Journal, 2009, 8, 225.	0.8	40
74	Cancer in Rheumatoid Arthritis: Occurrence, Mortality, and Associated Factors in a South European Population. Seminars in Arthritis and Rheumatism, 2008, 37, 388-397.	1.6	97
75	Adverse Reactions Related to the Administration of TNF Inhibitors. Analysis of a Registry of Biologic Therapy. ReumatologÃa ClÃnica (English Edition), 2008, 4, 90-95.	0.2	4
76	Trends towards improved disease state in Rheumatoid Arthritis over time: the influence of new therapies and changes in management approach: analysis of the EMECAR cohort. Arthritis Research and Therapy, 2008, 10, R138.	1.6	34
77	Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Research and Therapy, 2008, 10, R30.	1.6	387
78	Prevalence of Paget's disease of bone in Spain. Bone, 2008, 43, 1006-1009.	1.4	38
79	Nutritional Status and its Correlates in Equatorial Guinean Preschool Children: Results from a Nationally Representative Survey. Food and Nutrition Bulletin, 2008, 29, 49-58.	0.5	21
80	Predicted distribution and movement of Glossina palpalis palpalis (Diptera: Glossinidae) in the wet and dry seasons in the Kogo trypanosomiasis focus (Equatorial Guinea). Journal of Vector Ecology, 2007, 32, 218.	0.5	8
81	All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Annals of the Rheumatic Diseases, 2007, 66, 880-885.	0.5	196
82	Transmission of malaria and genotypic variability of Plasmodium falciparum on the Island of Annobon (Equatorial Guinea). Malaria Journal, 2007, 6, 141.	0.8	6
83	Spanish Registry for Adverse Events of Biological Therapy in Rheumatic Diseases (BIOBADASER): State Report, January 26th, 2006. ReumatologÃa ClÃnica (English Edition), 2007, 3, 4-20.	0.2	5
84	Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis and Rheumatism, 2007, 57, 756-761.	6.7	378
85	Evaluation of the efficacy of a topically administered combination of imidacloprid and permethrin against Phlebotomus perniciosus in dog. Veterinary Parasitology, 2007, 143, 375-379.	0.7	42
86	Spatial and temporal variability of the Glossina palpalis palpalis population in the Mbini focus (Equatorial Guinea). International Journal of Health Geographics, 2007, 6, 36.	1.2	12
87	Spatial variability in the density, distribution and vectorial capacity of anopheline species in a high transmission village (Equatorial Guinea). Malaria Journal, 2006, 5, 21.	0.8	41
88	Impact of different strategies to control Plasmodium infection and anaemia on the island of Bioko (Equatorial Guinea). Malaria Journal, 2006, 5, 10.	0.8	24
89	Evaluation of a spray of permethrin and pyriproxyfen for the protection of dogs against Phlebotomus perniciosus. Veterinary Record, 2006, 159, 206-209.	0.2	21